3D Systems and Ekso Bionics(TM) Announce First "Bespoke" Exoskeleton
RICHMOND, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it recently debuted the first ever 3D printed hybrid exoskeleton robotic suit, in collaboration with 3D Systems (NYSE:DDD), at a Singularity University event in Budapest. Designers from 3D Systems created personalized three-dimensional elements from multiple 3D scans taken of Ekso Ambassador, Amanda Boxtel.
"I believe that the most beautiful and functional designs have already been patented by nature, and inspired by Amanda's incredible spirit, we were able to harness nature's beauty with 3D printed functionality and freedom of creation to allow her body and spirit to soar," said Avi Reichental, President and CEO of 3DS. "3DS has long been a pioneer in patient-specific devices, integrating our cutting-edge 3D capabilities with robotics to better serve humanity opens new and unimaginable frontiers."
The state of the art Ekso robot was integrated with 3D printed components to create the first ever customized suit. "We are pleased to partner with 3D Systems on pioneering work," said Russ Angold, Ekso Bionics' Chief Technology Officer. "Our mission is to redefine what's possible; Ekso has proven to be a compelling tool for rehabilitation centers that have enabled thousands to walk in EksoTM and Ekso GTTM. Collaborating with 3D Systems allows us to experiment and look towards the future when custom exoskeletons for individuals will be available."
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics' lead product, EksoTM, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.
About Ekso Bionics
Since 2005, Ekso Bionics (http://www.eksobionics.com) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube: https://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K filed on January 23, 2014. The Company does not undertake to update these forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
Released February 19, 2014